Please register to access this content.
To continue viewing the content you love, please sign in or create a new account
Dismiss
This content is for our paying subscribers only

World Europe

COVID-19: UK minister says vaccine manufacturing is ‘lumpy’, supply not as good as hoped

Any new manufacturing process has challenges at the outset, says Zahawi



88-year-old Trevor Cowlett receives the Oxford University/AstraZeneca COVID-19 vaccine at the Churchill Hospital in Oxford, England.
Image Credit: AP

London: Britain’s vaccine rollout is limited by “lumpy” manufacturing and Pfizer’s changes to its production could lead to brief supply disruption, Vaccine Deployment Minister Nadhim Zahawi said on Monday.

Zahawi told LBC radio that the United Kingdom was hoping for 2 million vaccines a week from AstraZeneca but that those numbers will not be reached until mid February.

“It’s been a bit lumpy,” Zahawi said of vaccine manufacture.

Getting better

“There’s bound to be delays. Any new manufacturing process has challenges at the outset, it is lumpy, it begins to stabilise and get better and better week in, week out,” he told the BBC.

“The Pfizer BioNTech vaccine is a messenger RNA chemical, difficult chemical to manufacture, very very challenging but they’re doing really well, they want to do more which is why they’re reconfiguring to add volume to the whole world. That could delay supply but I’m confident we can meet our target.”

Advertisement